BioXcel Therapeutics (BTAI) Free Cash Flow (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Free Cash Flow of -$11.8 million for Q1 2026, up 1.94% year-over-year from -$11.6 million in Q1 2025, and up 16.9% quarter-over-quarter from -$14.2 million in Q4 2025.
BioXcel Therapeutics (BTAI) Free Cash Flow (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$11.8 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 1.94% year-over-year to -$11.8 million; the TTM figure through Mar 2026 stood at -$57.4 million (up 13.54% YoY), while the FY2025 annual figure was -$57.6 million, up 20.01% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$11.8 million, up from -$14.2 million in the prior quarter.
- The five-year high for Free Cash Flow was -$11.8 million in Q1 2026, with the low at -$52.4 million in Q1 2023.
- The 5-year median for Free Cash Flow is -$23.2 million (2024), against an average of -$25.4 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow tumbled 97.94% in 2022, then soared 66.18% in 2024.
- BioXcel Therapeutics' Free Cash Flow stood at -$38.6 million in 2022, then surged by 30.48% to -$26.9 million in 2023, then surged by 44.87% to -$14.8 million in 2024, then gained by 4.04% to -$14.2 million in 2025, then rose by 16.9% to -$11.8 million in 2026.
- Business Quant data shows BTAI's Free Cash Flow at -$11.8 million in Q1 2026, -$14.2 million in Q4 2025, and -$18.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.25 Mn | 24.25 Mn | 160,000.00 | -6.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.10 Mn |
| Jun 30, 2026 | -6.10 Mn |
| Mar 31, 2026 | -11.81 Mn |
| Mar 31, 2026 | -11.81 Mn |
| Dec 31, 2025 | -14.21 Mn |
| Dec 31, 2025 | -14.21 Mn |
| Sep 30, 2025 | -18.79 Mn |
| Sep 30, 2025 | -18.79 Mn |
| Jun 30, 2025 | -12.58 Mn |
| Jun 30, 2025 | -12.58 Mn |
| Mar 31, 2025 | -12.04 Mn |
| Mar 31, 2025 | -12.04 Mn |
| Dec 31, 2024 | -14.81 Mn |
| Dec 31, 2024 | -14.81 Mn |
| Sep 30, 2024 | -16.34 Mn |
| Sep 30, 2024 | -16.34 Mn |
| Jun 30, 2024 | -23.17 Mn |
| Jun 30, 2024 | -23.17 Mn |
| Mar 31, 2024 | -17.71 Mn |
| Mar 31, 2024 | -17.71 Mn |